neotripapdl1: dynamics of tils & pd-l1 expression in breast cancer
Published 4 years ago • 371 plays • Length 4:22Download video MP4
Download video MP3
Similar videos
-
1:38
combined analyses of pd-l1 and tils for therapy selection in tnbc
-
2:47
current treatment landscape of triple negative breast cancer
-
3:26
chemo-immunotherapy for tnbc
-
1:14
the importance of a biomarker-directed approach in triple-negative breast cancer
-
0:41
the importance of brca-1 testing in triple negative breast cancer
-
1:30
emerging immunotherapy beyond checkpoint inhibitors for tnbc
-
1:58
ascent-04: sacituzumab govitecan and pembrolizumab in pd-l1-positive tnbc
-
1:07
neotrip: efs in neoadjuvant atezolizumab with taxane/carboplatin ± anthracycline in high-risk tnbc
-
4:38
alice: atezolizumab immunogenic chemotherapy in metastatic tnbc
-
1:43
the role of the checkpoint inhibitors in breast cancer
-
5:25
investigational pd-l1–targeted immunotherapy safe for patients with triple-negative breast cancer
-
1:03
new directions in immunotherapy for improving outcomes in tnbc
-
2:10
testing and targeted therapy in triple negative breast cancer: 2023 west oncology
-
1:04:28
harnessing the immune system in the treatment of triple-negative breast cancer
-
3:37
case 3: pd-l1 testing used in triple-negative breast cancer
-
4:13
where does immuno-oncology fit in the treatment landscape of tnbc?
-
4:20
keynote-522: 5-year follow-up of pembrolizumab in triple-negative breast cancer
-
1:16
dr. tolaney on platinum-based therapy in neoadjuvant setting of tnbc
-
0:56
why does breast cancer come back?